Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CBRS18135 / A011502 / Brian Yirinec

Research Question:
How well does aspirin work in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy?

Basic Study Information

Purpose:
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

Location: University of Rochester Medical Center
Study Reference #: CBRS18135

Lead Researcher (Principal Investigator)

Lead Researcher:  Brian Yirinec

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search